electroCore 2025 Q1 Earnings Narrowed EPS Loss Amid Increased Revenue

electroCore (ECOR) reported its fiscal 2025 Q1 earnings on May 07th, 2025. The company's financial results for the first quarter ended March 31, 2025, revealed a 23% increase in revenue compared to the same period in 2024. While the company demonstrated improved revenue performance, it continued to face challenges with its net loss, which widened year-over-year. The guidance for the full year of 2025 includes anticipated revenue of approximately $30.0 million, indicating a positive outlook for the remainder of the fiscal year. Investors should note the closing of the NeuroMetrix acquisition, which is expected to contribute significantly to revenue by the year-end.

Revenue

The total revenue of electroCore increased by 23.4% to $6.72 million in 2025 Q1, up from $5.44 million in 2024 Q1.

Earnings/Net Income

electroCore narrowed losses to $0.47 per share in 2025 Q1 from a loss of $0.53 per share in 2024 Q1 (11.3% improvement). Meanwhile, the company's net loss widened to $-3.85 million in 2025 Q1, representing a 10.0% increase from the $-3.51 million loss recorded in 2024 Q1. The Company has sustained losses for 9 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. EPS indicates a slight improvement year-over-year.

Price Action

The stock price of electroCore has edged down 2.30% during the latest trading day, has dropped 7.41% during the most recent full trading week, and has surged 20.32% month-to-date.

Post Earnings Price Action Review

The strategy of buying ElectroCore (ECOR) shares after a revenue raise and holding for 30 days yielded moderate returns over the past five years, with a maximum drawdown and relatively stable annualized returns. The maximum drawdown of -34.24% occurred in 2024, during which the strategy faced significant losses due to the broader market downturn and ECOR's own price decline. This reflects the strategy's vulnerability during market crashes. The annualized returns for the strategy were 4.77% over the past five years, indicating a stable and modest growth rate. This suggests that while the strategy provided consistent returns, they were not exceptionally high. Comparing this strategy's returns with those of the SPY ETF, it becomes clear that ECOR's revenue raise and subsequent holding period offered some gains but may not have been sufficient to outperform a passive investment in the market. In conclusion, buying ECOR shares after a revenue raise and holding for 30 days provided some stability, evidenced by the annualized returns. However, the maximum drawdown during market downturns highlights the strategy's limitations. Investors should consider these factors along with their risk tolerance and market outlook when deciding on an investment strategy.

CEO Commentary

"electroCore delivered continued growth in the first quarter, increasing total revenue 23% and growing total revenue excluding TAC-STIM by 29%," commented Dan Goldberger, CEO of electroCore, Inc. The revenue growth enabled us to further narrow our loss from operations and improve Adjusted EBITDA. Increased G&A expenses were incurred due to seasonality related to the filing of our Annual Report on Form 10-K, severance expenses, and one-time expenses related to the NeuroMetrix transaction. With the NeuroMetrix acquisition now closed, we are well-positioned as a significant player in non-invasive bioelectronic technology, addressing a larger opportunity with a more diversified product line.

Guidance

For the full year of 2025, we expect total revenue to be approximately $30.0 million and net cash used for the next three quarters to be between $3.8 and $4.3 million, with NeuroMetrix providing meaningful revenue by the year ending December 2025.

Additional News

In recent weeks, electroCore has completed the acquisition of NeuroMetrix, Inc., broadening its bioelectronic technology portfolio and accelerating growth in the chronic pain and wellness markets. This strategic move enhances its position as a significant player in non-invasive bioelectronic technologies. Additionally, electroCore's Truvaga™ product now integrates with the Apple Health app, marking a significant step in expanding its wellness offerings. Furthermore, the company's gammaCore technology has been recognized for its effectiveness in treating concussive symptoms associated with mild traumatic brain injuries, further establishing electroCore's presence in bioelectronic medicine. These developments underscore electroCore's commitment to innovation and expansion within its industry.